Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (28572)	3/23/1999 12:15:00 AM
From: Spekulatius	Respond to of 32384

I am indeed looking at Liposome. I like their concept of repackaging known drugs to enhance their profile (decrease toxicity etc.This minimizes the risk of their drug development IMHO. They have now Abelcet and have applicated for EVACET. It seems that they have found a profitable niche. ABELCET sells reasonable well such that LIPO is moderately profitable and generates enough cash flow to allow further development of their pipeline. LIPO looks like a comparatively low risk investment - not a ten bagger but doubling an investment in 2 years does not seem to be a bad deal for me... My take on biotech investment is to wait for drug approval and maybe for the first sales # coming in. This will tell,if the drug sells. A drug which does not sell is not worth anything, I learned this lesson watching CORR. Their drug Intellegrin looks good, but doesn't sell. I am not smart enough to understand clinical results and genetics so I prefer to let others taking the pioneering profits (and losses), I am just confident with 50% returns -:)